Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC. 866 were enrolled and 510 randomized. Median progression-free survival was 3.9 months with selumetinib + docetaxel and 2.8 months with placebo + docetaxel. Median overall survival was 8.7 months with selumetinib + docetaxel and 7.9 months with placebo + docetaxel. Objective response rate was 20.1% with selumetinib + docetaxel and 13.7% with placebo + docetaxel.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2998
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 5
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Selumetinib,Docetaxel
- Evidence Level
- A
- Clinical Significance
- Resistance
- Pubmed
- 28492898
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Docetaxel | Resitance or Non-Reponse | true |
| Selumetinib | Resitance or Non-Reponse | true |